Agenus Secures First Global Approval for BOT+BAL in Metastatic Colorectal Cancer

  • Armenia granted marketing authorizations for Agenus' Botvymo (botensilimab, BOT) and Evamplix (balstilimab, BAL) combination therapy for previously treated MSS metastatic colorectal cancer without active liver metastases.
  • The approvals, effective October 2, 2026, are the first of their kind globally and are conditional, valid for one year with annual renewals based on clinical updates.
  • The approvals follow a rigorous review of the complete registration dossier submitted under Eurasian Economic Union rules.
  • Botensilimab is a multifunctional, Fc-enhanced anti-CTLA-4 antibody, and Balstilimab is an anti-PD-1 antibody designed to sustain antitumor T-cell activity.

This approval marks a significant milestone for Agenus, as it is the first global marketing authorization for BOT+BAL. The combination therapy targets a specific subset of metastatic colorectal cancer patients who have limited treatment options, addressing a critical unmet need. The approval underscores the potential of immuno-oncology combinations to treat 'cold' tumors that respond poorly to conventional therapies. Agenus' ability to navigate regulatory pathways in emerging markets could set a precedent for future approvals in similar regions.

Regulatory Expansion
Whether Agenus can leverage this approval to secure marketing authorizations in other Eurasian Economic Union member countries.
Clinical Validation
The pace at which Agenus can provide annual clinical updates to maintain the conditional approvals in Armenia.
Market Access
How the availability of BOT+BAL through named-patient programs and the French AAC pathway will impact patient access and adoption.